Evidence map›Paper›PMID 24300918›Full record

ArticleBioorganic & medicinal chemistry2014

New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.

Mariana Ferrer-Casal, Catherine Li, Melina Galizzi, Carlos A Stortz, Sergio H Szajnman, Roberto Docampo, Silvia N J Moreno, Juan B Rodriguez

Open access · bronzeAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Research in pharmaceutical sciences · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Mariana Ferrer-CasalDepartamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina.
Catherine LiCenter for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
Melina GalizziCenter for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
Carlos A StortzDepartamento de Química Orgánica and CIHIDECAR, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina.
Sergio H SzajnmanDepartamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina.
Roberto DocampoCenter for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
Silvia N J MorenoCenter for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
Juan B RodriguezDepartamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina. Electronic address: jbr@qo.fcen.uba.ar.
University of Georgia · USUniversity of Buenos Aires · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARFundación Ciencias Exactas y Naturales · AR

Funding

Drug Discovery Consortium for Chagas DiseaseR01AI082542 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2009 to 2010
$2.2M
Targeting Host and Apicomplexan Isoprenoid PathwaysR33AI102254 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2014 to 2016
$1.3M
Targeting Host and Apicomplexan Isoprenoid PathwaysR21AI102254 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2012 to 2013
$408k
NIAID NIH HHS AI-082542NIAID NIH HHS AI-102254NIAID NIH HHS R01 AI082542NIAID NIH HHS R21 AI102254NIAID NIH HHS R33 AI102254
6 · The paper itself

Abstract

As part of our project pointed at the search of new antiparasitic agents against American trypanosomiasis (Chagas disease) and toxoplasmosis a series of 2-alkylaminoethyl-1-hydroxy-1,1-bisphosphonic acids has been designed, synthesized and biologically evaluated against the etiologic agents of these parasitic diseases, Trypanosoma cruzi and Toxoplasma gondii, respectively, and also towards their target enzymes, T. cruzi and T. gondii farnesyl pyrophosphate synthase (FPPS), respectively. Surprisingly, while most pharmacologically active bisphosphonates have a hydroxyl group at the C-1 position, the additional presence of an amino group at C-3 resulted in decreased activity towards either T. cruzi cells or TcFPPS. Density functional theory calculations justify this unexpected behavior. Although these compounds were devoid of activity against T. cruzi cells and TcFPPS, they were efficient growth inhibitors of tachyzoites of T. gondii. This activity was associated with a potent inhibition of the enzymatic activity of TgFPPS. Compound 28 arises as a main example of this family of compounds exhibiting an ED₅₀ value of 4.7 μM against tachyzoites of T. gondii and an IC₅₀ of 0.051 μM against TgFPPS.

Indexed as

Antiparasitic AgentsDiphosphonatesDrug DesignGeranyltranstransferaseStructure-Activity RelationshipToxoplasmaTrypanosoma cruziAntiparasitic AgentsDiphosphonatesGeranyltranstransferaseAntiparasitic agentsBisphosphonatesFarnesyl pyrophosphate synthaseToxoplasma gondiiTrypanosoma cruzi

Identifiers

PMID24300918
PMCPMC3902031
OpenAlexW2080979797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.